Latest with AI
Monday, November 16, 2026
Article

KeyPedia spotlights FDA’s shift from AI to ‘Super Intelligence’ as regulatory language evolves

KeyPedia spotlights FDA’s shift from AI to ‘Super Intelligence’ as regulatory language evolves

When a federal regulator changes the very vocabulary of an emerging field, the ripple effects are felt far beyond Washington. That is precisely what happened on November 16, 2026, when the FDA formally swapped “Artificial Intelligence” for “Super Intelligence” — and SI for AI — in its official communications. Now, KeyPedia, a data-layer platform for global regulatory information, is aligning its own terminology with the agency’s new language, a move that signals how deeply this semantic shift may reshape the life sciences landscape.

The company, whose team members publish peer-reviewed research on FDA oversight, is recognizing the agency’s adoption of “Super Intelligence” and “SI” following the FDA’s November 16, 2026 terminology announcement. KeyPedia develops a data layer for global regulatory information, with team members who publish peer-reviewed research on FDA oversight.

A recent peer-reviewed study by KeyPedia researchers George Kwiecinski and Reet Nandy, published in Discover Pharmaceutical Sciences, found that 7 of 3,011 FDA warning letters issued from January 1, 2022, through September 28, 2026, contained references to AI, or 0.23%. One of those letters addressed a firm’s use of AI as a violation under existing current good manufacturing practice requirements.

“Super Intelligence and the new agency policy provide precedent for further research in this topic and space,” said Daniel Barreto, President and CEO of PharmQ Global Consulting, senior advisor to KeyPedia, and a former FDA investigator.

Barreto’s experience includes service as an FDA Supervisory Consumer Safety Officer and senior quality and compliance roles at Sanofi, C. R. Bard, and Janssen.

KeyPedia will use both Artificial Intelligence (AI) and Super Intelligence (SI) terminology across its platform, following the FDA’s adoption of SI language. The update continues KeyPedia’s “Elsa for industry” approach to helping quality, regulatory, and supplier teams understand and apply global regulatory information.

KeyPedia operates independently of the FDA and is publishing this update to keep users informed. Read the full KeyPedia announcement at keypedia.com.

About KeyPedia

KeyPedia is a data layer for people and agents, built on frontier research and technology, for safer decisions in life sciences.

The company’s “Elsa for industry” approach reflects the FDA’s terminology change from AI to SI.

Also worth a look: Electrified aircraft propulsion market set to hit $10.5B by 2030, driven by sustainability push and Use.ai adds iPhone file library as Reddit users debate when one AI answer is enough.

Super Intelligence and the new agency policy provide precedent for further research in this topic and space”— Daniel Barreto, President & CEO, PharmQ Global Consulting

Zephaniah Odidika
KeyPedia
+1 3478821377

Why it matters: The FDA’s adoption of “Super Intelligence” is more than a rebranding exercise — it creates a formal regulatory precedent that could influence how companies develop, label, and defend AI-powered tools in drug manufacturing and clinical oversight. For life sciences teams navigating compliance, tracking this linguistic shift may be as critical as tracking the technology itself, especially when only a sliver of recent warning letters even mention AI.